8-K: Cencora Reports Strong Fiscal 2025 Second Quarter Results, Raises Adjusted EPS Guidance

Cencora's Q2 2025 revenue reached $75.5 billion, a 10.3% year-over-year increase, with adjusted diluted EPS guidance raised to $15.70-$15.95 for fiscal year 2025.

Summary

• Cencora, Inc. reported a 10.3% increase in revenue for the second quarter of fiscal year 2025, reaching $75.5 billion.
• GAAP diluted EPS was $3.68, compared to $2.09 in the prior year's second quarter.
• Adjusted diluted EPS increased by 16.3% to $4.42, from $3.80 in the prior year's second quarter.
• The company is raising its adjusted diluted EPS guidance for fiscal year 2025 to a range of $15.70 to $15.95, up from the previous range of $15.30 to $15.60.
• U.S. Healthcare Solutions revenue increased by 11.4% to $68.3 billion.
• International Healthcare Solutions revenue increased by 0.7% to $7.2 billion, or 5.7% on a constant currency basis.
• The company's Board of Directors declared a quarterly cash dividend of $0.55 per common share, payable on June 2, 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and raised guidance, indicating confidence in the company's future performance.

Positives

• Revenue increased by 10.3% year-over-year to $75.5 billion.
• GAAP diluted EPS increased by 76.1% to $3.68.
• Adjusted diluted EPS increased by 16.3% to $4.42.
• Fiscal year 2025 adjusted diluted EPS guidance was raised.
• U.S. Healthcare Solutions segment showed strong revenue growth of 11.4%.

Negatives

• International Healthcare Solutions segment operating income decreased by 17.3% as reported, or 13.9% on a constant currency basis.
• Net interest expense increased by 62.2% to $104.0 million due to increased debt from senior notes and a term loan to finance the RCA acquisition.

Risks

• The company's future performance is subject to risks and uncertainties detailed in their SEC filings.
• Fluctuations in foreign currency exchange rates could impact future results.
• Changes in inventory quantities, product mix, and manufacturer pricing practices could affect LIFO expense (credit).

Future Outlook

Cencora is updating its fiscal year 2025 financial guidance to reflect stronger earnings growth in the U.S. Healthcare Solutions segment and a lower contribution from the International Healthcare Solutions segment; adjusted diluted EPS is expected to be in the range of $15.70 to $15.95.

Management Comments

• Cencora's second quarter results reflect the strength of our value proposition as a healthcare services provider and the important role we play in the supply chain, driven by our pharmaceutical distribution footprint and complementary end-to-end services and solutions, said Robert P. Mauch, President and Chief Executive Officer of Cencora.
• We continue to advance our core business and enhance our capabilities, with a focus on elevating our solutions in the markets we serve.
• Cencora strives to enhance its leadership position in healthcare through our pharmaceutical centric strategy, best-in-class team members, and customer-focused approach, Mauch continued.
• We believe this leadership, coupled with our operational excellence and emphasis on productivity, drives our resilient financial performance now and will continue to drive it in the future.

Industry Context

Cencora's performance reflects the ongoing demand for pharmaceutical distribution and healthcare solutions, particularly in the U.S. market, driven by factors such as increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class and specialty products to physician practices and health systems.

Comparison to Industry Standards

• Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $290 billion in annual revenue.
• Cencora's performance can be compared to other major pharmaceutical distributors such as McKesson and Cardinal Health, considering factors like revenue growth, EPS, and segment performance.
• The acquisition of RCA is a strategic move to enhance Cencora's capabilities in the U.S. Healthcare Solutions segment, similar to how competitors expand through acquisitions and partnerships.

Stakeholder Impact

• Shareholders will benefit from the increased dividend and raised EPS guidance.
• Customers will benefit from Cencora's continued focus on enhancing its healthcare solutions.
• Employees will benefit from the company's growth and success.

Next Steps

• Cencora management will attend the Bank of America Global Healthcare Conference on May 13, 2025.
• Investors can access replays of the conference call via telephone and webcast.
• The company will continue to focus on advancing its core business and enhancing its capabilities.

Key Dates

Keywords

earnings, financial results, pharmaceutical distribution, healthcare solutions, Cencora, EPS, revenue